Journal of American Association for Pediatric Ophthalmology and Strabismus
Major articleRecombinant interferon alfa-2b in the treatment of vision-threatening capillary hemangiomas in childhood☆
References (13)
Hemangiomas in infancy and childhood
Pediatr Ann
(1987)- et al.
Corticosteroid treatment of cutaneous hemangiomas: how effective?
Clin Pediatr
(1978) Treatment of hemangiomatosis with recombinant interferon alfa
Semin Hematol
(1990)Clinical applications of research on angiogenesis
N Engl J Med
(1995)- et al.
Corticosteroid resistant orbital hemangioma with proptosis treated with interferon alfa-2a and partial tarsorrhaphy
J Pediatr Ophthalmol Strabismus
(1995) - et al.
Treatment of a massive orbital-capillary hemangioma with interferon alfa-2b: short term results
Arch Ophthalmol
(1992)
Cited by (41)
Therapeutic action protocol in angiomas
2009, PielA review of 58 patients with periorbital haemangiomas to determine appropriate cases for intervention
2008, Journal of Plastic, Reconstructive and Aesthetic SurgeryCitation Excerpt :Systemic steroids were previously used more frequently,8,38–40 but remain appropriate mainly for massive/multiple facial haemangiomas or patients with life threatening lesions, e.g. affecting the respiratory system.41,42 For those resistent to steroids, some use alpha-interferon.17,43–48 Whilst usually well tolerated, potential side effects include flu-like symptoms, T-cell suppression, growth retardation17,47 and spastic diplegia17 although this may be reduced by lowering the dosage.47
Treatment of capillary hemangiomas causing refractive and occlusional amblyopia
2007, Journal of AAPOSCancer pathology and angiogenesis
2007, Clinical Ophthalmic Oncology with CD-ROMCancer Pathology and Angiogenesis
2007, Clinical Ophthalmic OncologyOff-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2)
2007, Journal of the American Academy of DermatologyCitation Excerpt :The use of interferon alfa should, therefore, be limited to function-impairing or life-threatening hemangiomas. To this end, Hastings et al52 have reduced lesion size by 82% in 15 patients with orbital hemangiomas by using SQ interferon alfa-2b (3 × 106 U/m2/d for 3 months). Similarly, Ezekowitz et al46 noted regression of 50% or more in life- or vision-threatening hemangiomas that were resistant to corticosteroids in 18 of the 20 patients with interferon alfa-2a.
- ☆
Supported in part by a grant from Schering Canada Inc.